Finally, as ENO1 overexpression occurs in almost all PDA cases, and the immune response to it is a common feature of PDA patients, the use of the whole ENO1 sequence like in our strategy, is potentially applicable to all patients without the need of personalizing therapy. This evidence concerns the gene ENO1 and Patent ductus arteriosus.